Minalga Brian, Siskind Rona, Campbell Russell, Adamson Tyler, Cermak Mary Allegra, Davis Annet, Givens Eddie D, Dyer Molly, McCarthy Katie, Montañez Nicole A, White Rhonda
The Legacy Project, Office of HIV/AIDS Network Coordination, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Axle Informatics, Bethesda, Maryland, USA.
AJOB Empir Bioeth. 2025 Apr 28:1-15. doi: 10.1080/23294515.2025.2497753.
When clinical trials fail to enroll diverse study populations, a multitude of consequences can occur, including compromised validity and generalizability, safety and efficacy uncertainties, regulatory limitations, widened disparities, distrust in science and medicine, and undermined efforts to address urgent health needs. We developed the Representative Studies Rubric (RSR), a questionnaire that evaluates the extent to which clinical trials are designed to enroll representative study populations with a focus on age, ethnicity, drug use, gender, pregnancy, race, and sex assigned at birth. We used the RSR to conduct an analysis of all active studies in the NIH-funded HIV/AIDS Clinical Trials Networks (Networks) and identified patterns of research practices that may limit the participation of underrepresented populations, with ethical implications. The Networks subsequently formalized the RSR as a required protocol development tool for all future studies to correct exclusionary research practices with the goal to achieve more representative study populations.
当临床试验未能纳入具有多样性的研究人群时,可能会产生多种后果,包括有效性和普遍性受损、安全性和有效性存在不确定性、监管受限、差距扩大、对科学和医学的不信任,以及满足紧急健康需求的努力受到破坏。我们开发了代表性研究评估量表(RSR),这是一份问卷,用于评估临床试验在设计时纳入具有代表性研究人群的程度,重点关注年龄、种族、药物使用、性别、妊娠、种族以及出生时指定的性别。我们使用RSR对美国国立卫生研究院资助的艾滋病毒/艾滋病临床试验网络(各网络)中的所有正在进行的研究进行了分析,并确定了可能限制代表性不足人群参与的研究实践模式,这具有伦理意义。各网络随后将RSR正式确定为所有未来研究所需的方案制定工具,以纠正排他性研究实践,目标是实现更具代表性的研究人群。